Who We Are
We strive to improve your health by helping you achieve better sleep quality. That’s what we mean by making sleep count for more. Our proprietary aer+™ technology involves the application of vacuum over the outside of the neck. aer+™ can reduce sleep related airway narrowing which contributes to obstructive sleep apnea (OSA) and chronic snoring. This approach has advantages over existing treatments and is expected to vastly expand the number of people receiving effective therapy for these conditions and enjoying better sleep quality worldwide.
THE UNMET NEED
Sleep apnea is now believed to be the commonest chronic respiratory disease – more prevalent than asthma or emphysema. Untreated sleep apnea has serious medical consequences including shortened life expectancy and increased risk of stroke and heart attack.
Nearly 1 billion adults worldwide have sleep apnea. All races and geographies are affected.
Less than 5 percent are now receiving adequate treatment.
More than 80 percent of people are undiagnosed, and a high proportion of people treated for sleep apnea are not compliant with therapy.
Sleep apnea is one of the largest unmet medical needs for any disease state, yet treatment of sleep apnea offers medically meaningful benefits and is one of the most cost-effective of all medical interventions. There is a clear need for a better way to identify and treat sleep apnea globally.
The Sommetrics Newsroom is where you’ll find up-to-date information about the company, including the latest press releases, as well as media coverage on sleep disorders and the impact poor quality sleep and snoring can have on your health and bed partner. In our newsroom, we also host aerBlog, where our experts cover a variety of topics, including sleep disorders, product updates, patient and physician resources, recent news, global trends in the sleep industry and more. Have a topic? Contact us to submit a suggestion to our team of experts.
Recent Press Releases
Sommetrics Launches Pivotal Clinical Study of Its aerSleep II Product to Treat Sleep Apnea; Raises $11 Million in Series C Preferred Financing
VISTA, Calif. — September 29, 2021 — Sommetrics, a private company developing products and services to improve sleep health, today announced the launch of the pivotal clinical trial of its aerSleep® II device for the treatment of obstructive sleep apnea (OSA).
Sommetrics Receives IDE Approval From the FDA to Begin SUPRA Trial of aerSleep II for Treating Sleep Apnea
VISTA, Calif. — April 29, 2021 — Sommetrics is pleased to announce US Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) application to conduct a pivotal in-home clinical trial of its aerSleep II system.
Sommetrics Receives FDA Breakthrough Device Designation for Its aerSleep II Product to Treat Sleep Apnea
Sommetrics, a private company developing products and services to improve sleep health, today announced its lead sleep apnea product, aerSleep II, has received FDA Breakthrough Device designation. This program allows for additional FDA feedback to sponsors during the pre-marketing phase…
Recent aerBlog Posts
Sommetrics is focused on improving health and well-being by optimizing sleep quality. Using our proprietary aer+ technology, our initial focus is on developing solutions for disorders related to the narrowing of the airway during sleep, such as obstructive sleep apnea (OSA) and chronic snoring.
Ask the Expert: Sleep Apnea, More Than Just a Snoring and Sleepiness Problem by Jerrold Alan Kram, M.D., FCCP, FAASM
More and more people are aware of the fact that snoring can be more than a simple annoyance, but may also be associated with poor quality sleep, awakenings, unrefreshed feeling and headaches in the morning, as well as other consequences on daytime function.
Ask the Expert: A New Approach to the Treatment of Obstructive Sleep Apnea by Jerrold Alan Kram, M.D., FCCP, FAASM
Q: Are there any new approaches to treating obstructive sleep apnea?
Obstructive sleep apnea (OSA) is an extremely common condition often estimated to be present in more than 10% of all adults. It is apnea, or difficulty breathing, that only occurs when we sleep. It is attributed to a combination of a patient’s anatomy and physiology. Anatomically, many patients with OSA have narrow or crowded pharyngeal areas, but the crucial change is in the physiology.